Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 11,464 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 11,464 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $23.10, for a total transaction of $264,818.40. Following the transaction, the chief financial officer now owns 23,382 shares of the company’s stock, valued at $540,124.20. This trade represents a 32.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Wednesday, March 19th, Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $23.10, for a total transaction of $205,104.90.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock opened at $23.08 on Thursday. The stock has a 50-day simple moving average of $20.16 and a 200-day simple moving average of $22.08. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -164.85 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter last year, the business earned $0.35 EPS. As a group, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on KNSA shares. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $37.17.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in KNSA. GSA Capital Partners LLP acquired a new stake in Kiniksa Pharmaceuticals in the 3rd quarter worth $268,000. Segall Bryant & Hamill LLC bought a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $675,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Kiniksa Pharmaceuticals by 40.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock valued at $8,098,000 after acquiring an additional 92,985 shares in the last quarter. Cerity Partners LLC bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at $834,000. Finally, Algert Global LLC increased its position in Kiniksa Pharmaceuticals by 390.0% in the third quarter. Algert Global LLC now owns 91,159 shares of the company’s stock worth $2,278,000 after purchasing an additional 72,556 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.